JP2010519206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519206A5 JP2010519206A5 JP2009549637A JP2009549637A JP2010519206A5 JP 2010519206 A5 JP2010519206 A5 JP 2010519206A5 JP 2009549637 A JP2009549637 A JP 2009549637A JP 2009549637 A JP2009549637 A JP 2009549637A JP 2010519206 A5 JP2010519206 A5 JP 2010519206A5
- Authority
- JP
- Japan
- Prior art keywords
- substituent
- optionally substituted
- optionally
- nr6r7
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001424 substituent group Chemical group 0.000 claims 132
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- -1 pyrrolo [2,3] pyrimidyl Chemical group 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000004438 haloalkoxy group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 4
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 3
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 102000004310 Ion Channels Human genes 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims 2
- 125000005605 benzo group Chemical group 0.000 claims 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 2
- 125000005945 imidazopyridyl group Chemical group 0.000 claims 2
- 230000005931 immune cell recruitment Effects 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000005888 tetrahydroindolyl group Chemical group 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- NUIDMUUKGHMEKR-UHFFFAOYSA-N 2,6-difluoro-n-(5-phenyl-8,9-dihydro-7h-benzo[7]annulen-2-yl)benzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C2C(C=3C=CC=CC=3)=CCCCC2=C1 NUIDMUUKGHMEKR-UHFFFAOYSA-N 0.000 claims 1
- UOXYJSHABNCKNS-UHFFFAOYSA-N 2,6-difluoro-n-(6-methyl-5-phenyl-8,9-dihydro-7h-benzo[7]annulen-2-yl)benzamide Chemical compound C12=CC=C(NC(=O)C=3C(=CC=CC=3F)F)C=C2CCCC(C)=C1C1=CC=CC=C1 UOXYJSHABNCKNS-UHFFFAOYSA-N 0.000 claims 1
- QAMPHGFSHGCJIX-UHFFFAOYSA-N 2,6-difluoro-n-[5-(1-hydroxypropan-2-ylidene)-7,8-dihydro-6h-naphthalen-2-yl]benzamide Chemical compound C=1C=C2C(=C(CO)C)CCCC2=CC=1NC(=O)C1=C(F)C=CC=C1F QAMPHGFSHGCJIX-UHFFFAOYSA-N 0.000 claims 1
- HWXCHHLTRJYJAQ-UHFFFAOYSA-N 2,6-difluoro-n-[5-(1-morpholin-4-yl-1-oxopropan-2-ylidene)-7,8-dihydro-6h-naphthalen-2-yl]benzamide Chemical compound C1CCC2=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=C2C1=C(C)C(=O)N1CCOCC1 HWXCHHLTRJYJAQ-UHFFFAOYSA-N 0.000 claims 1
- ZKXLUFVYPVWURV-UHFFFAOYSA-N 2-[6-[(2,5-difluorobenzoyl)amino]-3,4-dihydro-2h-naphthalen-1-ylidene]propyl acetate Chemical compound C=1C=C2C(=C(C)COC(=O)C)CCCC2=CC=1NC(=O)C1=CC(F)=CC=C1F ZKXLUFVYPVWURV-UHFFFAOYSA-N 0.000 claims 1
- IIOKZLFWNFGSCR-UHFFFAOYSA-N 2-[6-[(2,6-difluorobenzoyl)amino]-3,4-dihydro-2h-naphthalen-1-ylidene]propanoic acid Chemical compound C=1C=C2C(=C(C(O)=O)C)CCCC2=CC=1NC(=O)C1=C(F)C=CC=C1F IIOKZLFWNFGSCR-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 102000000743 Interleukin-5 Human genes 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 241000243985 Onchocerca volvulus Species 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 208000024035 chronic otitis media Diseases 0.000 claims 1
- 206010011005 corneal dystrophy Diseases 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 1
- 208000013256 infectious meningitis Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- XNMOKWWWKFDIJO-UHFFFAOYSA-N methyl 2-[6-[(2,6-difluorobenzoyl)amino]-3,4-dihydro-2h-naphthalen-1-ylidene]propanoate Chemical compound C=1C=C2C(=C(C)C(=O)OC)CCCC2=CC=1NC(=O)C1=C(F)C=CC=C1F XNMOKWWWKFDIJO-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- XEPFNBTVFLNZNY-UHFFFAOYSA-N n-[5-(4-acetamidophenyl)-8,9-dihydro-7h-benzo[7]annulen-2-yl]-2,6-difluorobenzamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CCCCC2=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=C12 XEPFNBTVFLNZNY-UHFFFAOYSA-N 0.000 claims 1
- PUQPKMHRRQJQLH-UHFFFAOYSA-N n-[5-(4-aminophenyl)-8,9-dihydro-7h-benzo[7]annulen-2-yl]-2,6-difluorobenzamide Chemical compound C1=CC(N)=CC=C1C1=CCCCC2=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=C12 PUQPKMHRRQJQLH-UHFFFAOYSA-N 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 208000002042 onchocerciasis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 206010044325 trachoma Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90194907P | 2007-02-16 | 2007-02-16 | |
| PCT/US2008/002077 WO2008103310A1 (en) | 2007-02-16 | 2008-02-15 | Substituted fused-ring compounds for inflammation and immune-related uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010519206A JP2010519206A (ja) | 2010-06-03 |
| JP2010519206A5 true JP2010519206A5 (https=) | 2011-03-31 |
Family
ID=39710369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549637A Pending JP2010519206A (ja) | 2007-02-16 | 2008-02-15 | 炎症及び免疫関連使用のための置換縮合環化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8809396B2 (https=) |
| EP (1) | EP2129219A4 (https=) |
| JP (1) | JP2010519206A (https=) |
| AU (1) | AU2008219115A1 (https=) |
| CA (1) | CA2678615A1 (https=) |
| TW (1) | TW200901961A (https=) |
| WO (1) | WO2008103310A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI444187B (zh) | 2005-01-25 | 2014-07-11 | Synta Pharmaceuticals Corp | 用於炎症及免疫相關用途之噻吩化合物 |
| WO2007087442A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted biaryl compounds for inflammation and immune-related uses |
| WO2007087441A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
| WO2007087443A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
| US8119643B2 (en) | 2006-03-20 | 2012-02-21 | Synta Pharmaceuticals Corp. | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses |
| US8779154B2 (en) | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| DK2563776T3 (en) | 2010-04-27 | 2016-09-19 | Calcimedica Inc | Relations that modulate intracellular calcium |
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| AU2011248579A1 (en) | 2010-04-27 | 2012-11-29 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2609095A4 (en) | 2010-08-27 | 2014-06-18 | Calcimedica Inc | COMPOUNDS MODULATING INTRACELLULAR CALCIUM |
| US20120316182A1 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US9856240B2 (en) | 2011-10-19 | 2018-01-02 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2013077186A1 (ja) * | 2011-11-21 | 2013-05-30 | 国立大学法人筑波大学 | 活性調節剤、これを含有する医薬品、ＣＤ３００ａ遺伝子欠損マウスの使用および抗ＣＤ３００ａ抗体 |
| WO2014059333A1 (en) | 2012-10-12 | 2014-04-17 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2014073529A1 (ja) * | 2012-11-07 | 2014-05-15 | 国立大学法人筑波大学 | アレルギー疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用 |
| ES3033759T3 (en) | 2015-02-27 | 2025-08-07 | Calcimedica Inc | Pancreatitis treatment |
| CA2995094A1 (en) | 2015-08-07 | 2017-02-16 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
| US20230242640A1 (en) * | 2018-08-22 | 2023-08-03 | Ose Immunotherapeutics | ANTI-SIRPg Compounds |
| SG11202102491RA (en) | 2018-09-14 | 2021-04-29 | Rhizen Pharmaceuticals A G | Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof |
| KR20220140515A (ko) | 2020-01-13 | 2022-10-18 | 버지 애널리틱스, 인크. | 치환된 피라졸로-피리미딘 및 그의 용도 |
| CA3172249A1 (en) | 2020-03-20 | 2021-09-23 | Calcimedica, Inc. | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome |
| CA3198798A1 (en) | 2020-11-13 | 2022-05-19 | Kenneth Stauderman | Improved synthesis of crac channel inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1793518A1 (de) * | 1964-10-02 | 1972-02-03 | Searle & Co | Verfahren zur Herstellung von 1-Vinyltetralolen |
| PT87487B (pt) * | 1987-05-15 | 1992-09-30 | Schering Corp | Processo para a preparacao de derivados de naftaleno, benzoxepina, benzazepina e benzociclo-hepteno |
| JP2000511558A (ja) * | 1996-06-21 | 2000-09-05 | アラーガン・セイルズ・インコーポレイテッド | レチノイドおよび／またはレチノイド拮抗剤様生物学的活性を有する置換テトラヒドロナフタレンおよびジヒドロナフタレン誘導体 |
| DE19805370A1 (de) * | 1997-03-14 | 1998-09-17 | Gruenenthal Gmbh | Substituierte Aminoverbindungen und ihre Verwendung als analgetisch wirksame Substanzen |
| DE19833786A1 (de) * | 1998-07-18 | 2000-01-20 | Schering Ag | Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| JP2002529444A (ja) * | 1998-11-12 | 2002-09-10 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 二環式シグナル伝達阻害剤、それを含む組成物とその用途 |
| DE69915692T2 (de) | 1998-12-22 | 2005-02-10 | Tanabe Seiyaku Co., Ltd. | Inhibitoren der alpha-4 beta-1 vermittelten zelladhäsion |
| JP2004501147A (ja) * | 2000-06-20 | 2004-01-15 | アセロジエニクス・インコーポレイテツド | １，３−ビス−（置換フェニル）−２−プロペン−１−オン類およびｖｃａｍ−１媒介障害を治療するためのそれらの使用 |
| JP2004002402A (ja) * | 2002-04-24 | 2004-01-08 | Takeda Chem Ind Ltd | Ｃｃｒ拮抗作用を有する化合物の用途 |
| CA2483253A1 (en) * | 2002-04-24 | 2003-11-06 | Takeda Pharmaceutical Company Limited | Use of compounds having ccr antagonism |
| JP2004196702A (ja) * | 2002-12-18 | 2004-07-15 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド誘導体又はその塩 |
| ES2222833B1 (es) | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos. |
| DE102004044680B3 (de) * | 2004-09-09 | 2006-06-08 | Schering Ag | Alkyliden-Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate |
| WO2006065842A2 (en) * | 2004-12-13 | 2006-06-22 | Synta Pharmaceuticals Corp. | 5,6,7,8-tetrahydroquinolines and related compounds and uses thereof |
| US7863270B2 (en) * | 2005-05-13 | 2011-01-04 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
-
2008
- 2008-02-15 EP EP08725685A patent/EP2129219A4/en not_active Withdrawn
- 2008-02-15 JP JP2009549637A patent/JP2010519206A/ja active Pending
- 2008-02-15 CA CA002678615A patent/CA2678615A1/en not_active Abandoned
- 2008-02-15 TW TW097105319A patent/TW200901961A/zh unknown
- 2008-02-15 WO PCT/US2008/002077 patent/WO2008103310A1/en not_active Ceased
- 2008-02-15 AU AU2008219115A patent/AU2008219115A1/en not_active Abandoned
-
2009
- 2009-08-14 US US12/541,623 patent/US8809396B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010519206A5 (https=) | ||
| CA2669695A1 (en) | Tetrahydropyridinyl compounds for inflammation and immune-related uses | |
| JP2010509342A5 (https=) | ||
| TWI831325B (zh) | 作為atr抑制劑的萘啶衍生物及其製備方法 | |
| JP2010535218A5 (https=) | ||
| JP2021532124A (ja) | Ｎｌｒｐ３インフラマソーム阻害剤 | |
| JP2020537657A5 (https=) | ||
| RU2328499C2 (ru) | Производные пирролопиридазина, фармацевтическая композиция, способ профилактики или лечения заболеваний, применение в качестве ингибитора фосфодиэстеразы iv, и/или продуцирования tnf | |
| JP2019163290A5 (https=) | ||
| TWI627174B (zh) | Ｐ２ｘ７調控劑 | |
| JP2020528889A5 (https=) | ||
| JP2017501234A5 (https=) | ||
| JP6387361B2 (ja) | ピリジン−４−イル誘導体 | |
| JP2017505808A5 (https=) | ||
| WO2007116866A1 (ja) | ヘテロ化合物 | |
| JPH0346474B2 (https=) | ||
| JP4669839B2 (ja) | ジフェニルピリジン誘導体、その製造法および治療用途 | |
| JP2012528105A5 (https=) | ||
| JP2019514956A (ja) | 置換イミダゾ［１，２−ｂ］ピリダジン、置換イミダゾ［１，５−ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用 | |
| JP2012504604A5 (https=) | ||
| CN102388052A (zh) | 调节硬脂酰基-CoA去饱和酶的螺环衍生物 | |
| CA3068128A1 (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| JP7305198B2 (ja) | 肝臓送達に基づくエンテカビルプロドラッグであるヌクレオシドの環状リン酸エステル化合物および応用 | |
| JP2018502083A5 (https=) | ||
| JP6513075B2 (ja) | オートタキシン阻害活性を有する縮合ピラゾール誘導体 |